Pharma Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Data
Clinical Data announces 2006 launch of genetic test for warfarin response
July 4th, 2006
Clinical Data, Inc. (CLDA) announced that its PGxHealth division will provide a genetic test to clinicians that is associated with response to warfarin, a commonly prescribed drug to treat and prevent blood clots associated with stroke, heart attack, and other clotting disorders. The ability to provide this test is a direct result of Clinical Data's recent execution of intellectual property licenses under which the company has been granted commercialization rights relating to certain polymorphisms in the Vitamin K epoxide reductase complex gene (VKORC1; also known as VKOR). Polymorphisms within the VKORC1 gene are one of the important predictors of response to warfarin....
Source: Pharma Law Weekly (2006-07-04)
|
